Bristol-Myers Squibb beat Q4 earnings expectations, but the stock fell due to lowered 2025 revenue guidance and patent concerns. See why I rate BMY as a Hold.

Drugmaker Bristol Myers Squibb has been a standout among its big pharma peers over the past six months, scoring a share-price gain of more than 20%, while most of the group has been flat or down. Financial results the company reported early Thursday seem to validate that recent performance,

Bristol-Myers Squibb shares dropped nearly 4% Thursday morning, on track to hit their lowest point in over two weeks. Despite a strong fourth-quarter (Q4) performance, the company's 2025 outlook disappointed Wall Street,